Log in
Enquire now
OncoImmune

OncoImmune

A clinical-stage biopharmaceutical company engaging in drug discovery and drug development for treating autoimmune disease and cancer.

OverviewStructured DataIssuesContributors
Is a
Organization
Organization
Company
Company
Acquisition Transaction
‌
Acquisition of OncoImmune by Merck
B2X
B2B
B2B
CIK Number
1,695,528
Company Operating Status
Active
Country
United States
United States
Crunchbase URL
crunchbase.com/organiz...coimmune
Email Address
admin@oncoimmune.com
Founded Date
1889
0
Founder
Pan Zheng
Pan Zheng
0
Yang LIU
Yang LIU
0
Industry
Biotechnology
Biotechnology
Autoimmune disease
Autoimmune disease
‌
CAR T-Cell therapy
Cell therapy
Cell therapy
Immunotherapy
Immunotherapy
Biology
Biology
Technology
Technology
Biopharmaceutical
Biopharmaceutical
Investors
HM Capital Partners
HM Capital Partners
Food and Drug Administration
Food and Drug Administration
National Cancer Institute
National Cancer Institute
3E Bioventures Capital (3E)
3E Bioventures Capital (3E)
‌
GF Xinde Investment Management
Kaitai Capital
Kaitai Capital
‌
GBA Fund
Latest Funding Round Date
September 2020
Latest Funding Round Amount (USD)
56,000,000
Latest Funding Type
Series B
Series B
LinkedIn URL
@company/merck
Location
Rockville, Maryland
Rockville, Maryland
Number of Employees (Ranges)
10,001+
0
Patents Assigned (Count)
8
Phone Number
+13015579119
Total Funding Amount (USD)
76,500,000
Official Website
oncoimmune.com
Wikidata ID
Q30281322

Find more companies like OncoImmune

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.